Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 4.59 ($0.06) and traded as low as GBX 4.50 ($0.06). Allergy Therapeutics shares last traded at GBX 5.42 ($0.07), with a volume of 493,909 shares.
Allergy Therapeutics Price Performance
The company has a debt-to-equity ratio of 37.22, a current ratio of 1.40 and a quick ratio of 1.48. The firm’s 50 day moving average is GBX 4.78 and its 200 day moving average is GBX 4.61. The firm has a market cap of £263.30 million, a P/E ratio of -91.67, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.
Allergy Therapeutics Company Profile
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Recommended Stories
- Five stocks we like better than Allergy Therapeutics
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- How Whitestone REIT is Transforming Sunbelt Retail Growth
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Top-Performing Non-Leveraged ETFs This Year
- Short Selling: How to Short a Stock
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
